Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA(1c), and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

A three-arm, randomized, double-masked, placebo-controlled phase 2b trial performed by the Type 1 Diabetes TrialNet Study Group previously demonstrated that low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg) preserved β-cell function and reduced HbA(1c) for 1 year in new-onset type 1 diabetes. Subje...

Descripción completa

Detalles Bibliográficos
Autores principales: Haller, Michael J., Long, S. Alice, Blanchfield, J. Lori, Schatz, Desmond A., Skyler, Jay S., Krischer, Jeffrey P., Bundy, Brian N., Geyer, Susan M., Warnock, Megan V., Miller, Jessica L., Atkinson, Mark A., Becker, Dorothy J., Baidal, David A., DiMeglio, Linda A., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Herold, Kevan C., Marks, Jennifer B., Moran, Antoinette, Rodriguez, Henry, Russell, William E., Wilson, Darrell M., Greenbaum, Carla J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2019
Materias:
Immunology and Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610026/
https://www.ncbi.nlm.nih.gov/pubmed/30967424
http://dx.doi.org/10.2337/db19-0057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610026/
https://www.ncbi.nlm.nih.gov/pubmed/30967424
http://dx.doi.org/10.2337/db19-0057

Ejemplares similares